NYSE: WATWaters Corp Stock
$332.10+3.26 (+0.99%)
Updated Sep 9, 2024
WAT Price
$332.10
Fair Value Price
N/A
Market Cap
$19.71B
52 Week Low
$231.90
52 Week High
$367.21
P/E
33.11x
P/B
13.96x
P/S
5.99x
PEG
2.8x
Dividend Yield
N/A
Revenue
$2.88B
Earnings
$595.69M
Gross Margin
59.7%
Operating Margin
27.31%
Profit Margin
20.7%
Debt to Equity
2.15
Operating Cash Flow
$705M
Beta
0.91
Next Earnings
Nov 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
WAT Overview
Waters Corporation manufactures, sells, and services ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, and other consumable products. Its MS technology instruments are used in clinical trial drug testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Waters was founded in 1958 and is headquartered in Milford, MA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how WAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WAT ($332.10) is trading above its intrinsic value of $96.60, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WAT is poor value based on its earnings relative to its share price (33.11x), compared to the US market average (24.05x)
P/E vs Market Valuation
WAT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more WAT due diligence checks available for Premium users.
Be the first to know about important WAT news, forecast changes, insider trades & much more!
WAT News
Valuation
WAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
33.11x
Industry
37.46x
Market
24.05x
WAT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
WAT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
WAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.96x
Industry
4.56x
WAT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WAT price to earnings growth (PEG)
For valuing profitable companies with growth potential
WAT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
WAT's financial health
Profit margin
Revenue
$708.5M
Net Income
$142.7M
Profit Margin
20.1%
WAT's Earnings (EBIT) of $785.45M... subscribe to Premium to read more.
Interest Coverage Financials
WAT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.4B
Liabilities
$3.0B
Debt to equity
2.15
WAT's short-term assets ($1.60B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WAT's long-term liabilities ($2.27B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$54.5M
Investing
-$36.1M
Financing
-$34.0M
WAT's operating cash flow ($705.34M)... subscribe to Premium to read more.
Debt Coverage Financials
WAT vs Diagnostic & Research Stocks
Waters Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.